Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents

a technology of mpl pathway and inhibitory agent, which is applied in the direction of aerosol delivery, metabolism disorder, fused cells, etc., can solve the problems of illness and death in adults, and achieve the effects of reducing platelet count, enhancing its regression, and inhibiting the development, progression or propagation of the condition

Inactive Publication Date: 2006-04-04
EMORY UNIVERSITY
View PDF33 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This approach effectively reduces the risk and progression of vaso-occlusive events like thrombotic events and abnormal vessel growth without significant adverse side effects, providing a medical benefit by lowering platelet counts in a controlled manner.

Problems solved by technology

Conditions resulting from thrombotic or thromboembolic events are the leading causes of illness and death in adults in western civilization.
Notwithstanding the effort and financial resources that have been invested, these conditions still account for the vast majority of illness and death in the adult populations of developed nations.
The mechanism through which aspirin exerts its therapeutic effect however is controversial since in addition to affecting platelets, aspirin is also known to possess anti-inflammatory properties.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0033]Unexpectedly, the invention involves the discovery that treating human subjects, especially those who do not have a hematological proliferative disorder, to induce a lower platelet count (such as to low normal levels or in some preferred instances to below normal levels) can have desirable medical benefit without significant adverse side effects.

[0034]The invention is premised in part on the discovery that a reduction in platelet count in a subject, such as for example to low normal and more preferably below normal levels, reduces the risk of a vaso-occlusive event such as a thrombotic event in the subject without significant adverse side effects. As used herein, a vaso-occlusive event is a event that is characterized by or results in a decrease in the internal diameter of blood vessels either locally or systemically to an extent which impedes blood flow in a subject and which for the purposes of the invention is of a pathological nature. Thus, a vaso-occlusive event embraces ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
densityaaaaaaaaaa
densityaaaaaaaaaa
diastolic pressureaaaaaaaaaa
Login to View More

Abstract

The invention relates to the treatment of subjects for the purpose inhibiting vaso-occlusive events, including thrombosis and embolism, by administering agents which reduce the number of circulating platelets to low or below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.

Description

RELATED APPLICATIONS[0001]This application is a continuation of U.S. Non-Provisional Patent Application Ser. No.: 10 / 117,837, filed Apr. 8, 2002, now abandoned which is a divisional of U.S. Non-Provisional Patent Application Ser. No. 09 / 666,224, filed Sep. 21, 2000, now U.S. Pat. No. 6,376,242 which claims priority to U.S. Provisional Patent Application filed Sep. 21, 1999, entitled “METHODS AND COMPOSITIONS FOR TREATING PLATELET-RELATED DISORDERS”, Ser. No. 60 / 154,929, the contents of all of which are incorporated by reference herein in their entirety.FIELD OF THE INVENTION[0002]The invention relates to methods, and products for treatment and / or prevention of platelet related thrombotic and other vaso-occlusive disorders.BACKGROUND OF THE INVENTION[0003]Conditions resulting from thrombotic or thromboembolic events are the leading causes of illness and death in adults in western civilization. A great deal of effort and monetary resources have been directed towards understanding the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): C12N5/16C12N9/00C12N9/74C12N9/48A61K45/00C12N5/00A61K9/00A61K9/06A61K9/20A61K31/00A61K31/4365A61K31/519A61K31/60A61K31/616A61K31/726A61K38/16A61K38/36A61K38/48A61K38/49A61K45/06A61K47/28A61P3/06A61P7/02A61P9/10A61P9/12A61P9/14A61P11/00A61P13/12A61P27/14A61P43/00
CPCA61K9/1647A61K9/204A61K47/34A61K45/06A61K38/49A61K31/616A61K31/60A61K31/557A61K31/522A61K31/00A61K31/4365A61K31/4965A61K31/519A61K2300/00A61P11/00A61P13/12A61P27/14A61P3/06A61P43/00A61P7/02A61P9/10A61P9/12A61P9/14
Inventor HANSON, STEPHEN R.
Owner EMORY UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com